Clinical Trial Update: Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of gemcitabine plus pazopanib for metastatic pancreatic cancer has been terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Votrient (Pazopanib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-06-09